Related Experiment Video

Updated: Sep 21, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Is prophylactic treatment after myocardial infarction evidence-based?

C Brotons1, F Calvo, P Cascant

  • 1Cardiology Department, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.

Family Practice
|December 16, 1998
PubMed

Insights

Evidence-based treatments for myocardial infarction (MI) show potential for improved outcomes. Increased use of beta-blockers and lipid-lowering drugs post-MI can further reduce ischemic events and mortality.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Myocardial infarction (MI) is a leading cause of mortality and morbidity worldwide.
  • Effective secondary prevention strategies are crucial for reducing recurrent ischemic events and improving long-term survival in MI patients.
  • Evidence-based guidelines recommend specific prophylactic treatments post-MI, including antiplatelets, beta-blockers, ACE inhibitors, and lipid-lowering drugs.

Purpose of the Study:

  • To evaluate the adherence to evidence-based prophylactic treatment recommendations following hospital discharge for myocardial infarction (MI).
  • To assess the utilization of these treatments in primary care settings one year after MI hospitalization.
  • To identify potential gaps in the implementation of secondary prevention strategies for MI survivors.

Main Methods:

  • A 1-year prospective study was conducted involving 380 patients discharged from a tertiary hospital after treatment for myocardial infarction (MI) between January 1 and December 31, 1995.
  • Data on medication prescriptions at hospital discharge and in primary care at 1-year follow-up were collected and analyzed.
  • Medication classes evaluated included aspirin, beta-blockers, calcium channel blockers, ACE inhibitors, nitrates, and cholesterol-lowering drugs.

Main Results:

  • At hospital discharge, 70% of patients received aspirin, 45% beta-blockers, 27% calcium channel blockers, 26% ACE inhibitors, and 40% nitrates.
  • Cholesterol-lowering drug prescription increased from 8% at discharge to 17% in primary care at 1 year.
  • Beta-blocker prescription decreased from 45% at discharge to 34% in primary care, while ACE inhibitor use was higher (57%) in patients with impaired ventricular function or heart failure.

Conclusions:

  • There remains significant potential to reduce the risk of further ischemic events and mortality in myocardial infarction (MI) survivors.
  • Optimizing the use of beta-blockers and lipid-lowering drugs in post-MI care is essential for enhancing secondary prevention.
  • Adherence to evidence-based treatment guidelines requires continuous monitoring and improvement in both hospital and primary care settings.
Abstract

More Related Videos

A Modified Simple Method for Induction of Myocardial Infarction in Mice04:29

A Modified Simple Method for Induction of Myocardial Infarction in Mice

Published on: December 3, 2021

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...